Assessing the future medical cost burden for the European health systems under alternative exposure-to-risks scenarios

Goryakin, Yevgeniy; Thiébaut, Sophie; Cortaredona, Sébastien; Lerouge, M. Aliénor; Cecchini, Michele; Feigl, Andrea B; Ventelou, Bruno

doi:10.1371/journal.pone.0238565

Cited by 26 publications

(19 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The largest share of healthcare costs is spent on noncommunicable diseases. In 27 EU countries and the UK, the direct costs of noncommunicable diseases (NCDs) are expected to increase by 0.8% annually from2014–2050, with population aging remaining the substantial driver of total healthcare expenditures [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Analysis of Healthcare Expenditures in Bulgaria

et al. 2022

View full text Add to dashboard Cite

The growth of public expenditure worldwide has set the priority on assessment of trends and establishment of factors which generate the most significant public costs. The goal of the current study is to review the tendencies in public healthcare expenditures in Bulgaria and to analyze the influence of the demographic, economic, and healthcare system capacity indicators on expenditures dynamics. A retrospective, top-down, financial analysis of the healthcare system expenditures was performed. Datasets of the National Statistical Institute (NSI), National Health Insurance Fund (NHIF), and National Center of Public Health and Analysis (NCPHA) were retrospectively reviewed from2014–2019 to collect the information in absolute units of healthcare expenditures, healthcare system performance, demographics, and economic indicators. The research showed that increasing GDP led to higher healthcare costs, and it was the main factor affecting the cost growth in Bulgaria. The number of hospitalized patients and citizens in retirement age remained constant, confirming that their impact on healthcare costs was negligible. In conclusion, the population aging, average life expectancy, patient morbidity, and hospitalization rate altogether impacted healthcare costs mainly due to the multimorbidity of older people and the rising need for outpatient hospital services and medications.

show abstract

Section: Introductionmentioning

confidence: 99%

Analysis of Healthcare Expenditures in Bulgaria

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Due to increasing nutrition awareness, and partially due to the increased financial burden of rising healthcare costs from NCDs, for example, or the aging society [ 6 ], the EU commenced a series of measures aimed to lower the rise of nutrition-related diseases [ 7 ]. In the late 1990s and early 2000s, nutrition and health claims were being used in the food and drink industry all over the world.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Time on Nutrition and Health Claims on the Irish Marketplace

Offe

Bebin

Lalor

2022

Foods

View full text Add to dashboard Cite

Since the implementation of Regulation (EC) No 1924/2006 on nutrition and health claims (NHCR) made on food, only 261 health claims have been authorised, suggesting that the regulation creates challenges for the food industry. This study looks at the prevalence of nutrition and health claims labelled on food on the Irish market. Specifically, we compared their prevalence in 2009 with those present on the marketplace in 2022. Food labels of defined food categories were examined in three nationwide supermarkets in Ireland, and data of claims made on these labels were collected. A series of statistical analyses was conducted to compare the results from 2021 with those of 2009. In 2021, around half of the examined products (52.8%) displayed at least one nutrition claim, showing no significant difference with the data collected in 2009 (53.5%). Individual categories, however, did exhibit changes between the two time points. The prevalence of health claims on food has decreased from 21.6% in 2009 to 10.5% in 2021. There will always be a time lag between when a regulation is enacted and what its true impact can be measured. This study provides these data for the impact of time on EU Regulation 1924/2006 on the Irish market.

show abstract

“…The same report outlined that only eleven out of 52 countries had reported that GDP growth was higher than the growth in healthcare costs, whereas, in 31, the share of public expenditure had risen more than twice the GDP. The direct costs associated with noncommunicable diseases (NCDs) are expected to grow by 0.8% per year in EU countries between 2014 and 2020, with the main factors leading to this being the aging EU population, as well as the introduction of new health technologies (3).…”

Section: Introductionmentioning

confidence: 99%

Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria

Mitkova

Dimitrova

Doneva

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

Central and Eastern European countries (CEEC) have among the highest rates of increase in healthcare expenditure. External reference pricing, generics and biologics price capping, regressive scale for price setting, health technology assessment (HTA), and positive drug lists for reimbursed medicines are among the variety of implemented cost-containment measures aimed at reducing and controlling the rising cost for pharmaceuticals. The aim of our study was to analyze the influence of a recently introduced measure in Bulgaria—budget capping in terms of overall budget expenditure. A secondary goal was to analyze current and extrapolate future trends in the healthcare and pharmaceutical budget based on data from 2016 to 2021. The study is a retrospective, observational and prognostic, macroeconomic analysis of the National Health Insurance Fund's (NHIF) budget before (2016–2018) and after (2019–2021) the introduction of the new budget cap model. Subgroups analysis for each of the three new budget groups of medicines (group A: medicines for outpatient treatment, prescribed after approval by a committee of 3 specialists; group B: all other medicines out of group A; and group C: oncology and life-saving medicines out of group A) was also performed, and the data were extrapolated for the next 3 years. The Kruskal–Wallis test was applied to establish statistically significant differences between the groups. During 2016–2021, healthcare services and pharmaceutical spending increased permanently, observing a growth of 82 and 80%, respectively. The overall healthcare budget increased from European €1.8 billion to 3.3 billion. The subgroup analysis showed a similar trend for all three groups, with similar growth between them. The highest spending was observed in group C, which outpaced the others mainly due to the particular antineoplastic (chemotherapy) medicines included in it. The rising overall healthcare cost in Bulgaria (from European €1.8 billion to 3.3 billion) reveals that implementation of a mechanism for budget predictability and sustainability is needed. The introduced budget cap is a relatively effective measure, but the high level of overspending and pay-back amount (from European €34 billion to 59 billion during 2019–2021) reveals that the market environmental risk factors are not well foreseen and practically implemented.

show abstract

Assessing the future medical cost burden for the European health systems under alternative exposure-to-risks scenarios

Cited by 26 publications

References 32 publications

Analysis of Healthcare Expenditures in Bulgaria

Analysis of Healthcare Expenditures in Bulgaria

The Impact of Time on Nutrition and Health Claims on the Irish Marketplace

Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria

Contact Info

Product

Resources

About